Drugs used in Diabetes
Overview
This report looks at prescribing trends in primary care for Drugs used in Diabetes at SICBL and ICB level with particular focus on insulins, anti-diabetic drugs and diagnostic & monitoring devices. Prescribing data is weighted with QOF registers, and also uses HES data to measure prescribing outcomes.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
April 2023 to March 2026
Blood Glucose Test Strips – MO opportunities
Overview
At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver on alongside their local medicines optimisation priorities. Progress against chosen opportunities will be reviewed using available data.
This report focuses on the appropriate prescribing and supply of blood glucose and ketone meters and testing strips and has data at SICBL, ICB and Commissioning Region level.
In 2023, NHS England published Commissioning recommendations following the national assessment of blood glucose and ketone meters, testing strips and lancets. This details the recommended meters, strips and lancets, that following evaluation have been determined to have the highest quality and be most cost effective.
NHS England Aim: to utilise the best value blood glucose and ketone meters, and testing strips.
The report is provided to NHS colleagues only, please do not share outside the NHS.
If you have problems accessing this file due to a security warning, please see this advice on opening the file. For further assistance, please email us at nuth.nyrdtc.rxsupp@nhs.net.
This publication is part of our Strategic Support and Planning contract. To gain access please email us at nuth.nyrdtc.rxsupp@nhs.net.
Frequency
Quarterly
Data period
April 2023 to March 2026
Fezolinetant – Prescribing Information leaflet
Prescribing information leaflets have been developed to support clinicians in the prescribing of drugs classified as Green, Green (following specialist initiation) or Green (following specialist recommendation initiation) drugs on the local formularies.
These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.
Switching from disposable to reusable insulin pens
This document outlines the benefits of appropriate switching from disposable to reusable insulin pens, highlighting advantages for patients, the environment, and potential cost savings. It also provides practical recommendations for implementation by medicines optimisation teams
Medicines value tracker – Metformin 1g tablets; opportunity savings realised
The purpose of the Medicines value bulletin tracker publications are to support ICBs in monitoring progress and identifying remaining potential opportunity savings, for the Medicines value opportunities already identified in the RDTC Medicines Value Bulletin series. The MVB tracker publications for Metformin 1g IR tablets cover all 7 ICBs across the North of England. Please select the appropriate version for your region below.
Formulary assessment – Hydrocortisone sodium phosphate 5mg/5ml, 10mg/5ml oral solutions
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
The information in this document is correct at the time of publication and formulations may change. This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Budget impact of metformin 1g immediate release tablet prescribing
The purpose of this bulletin is to highlight the rapid increase in price of metformin 1g tablets over the last year, and to raise awareness of the difference in price of metformin 1g immediate release (IR) tablets compared with 500mg IR tablets. It considers the potential budget impact to primary care of prescribing metformin 1g IR tablets across the ICBs in both the North East & Yorkshire and North West region
This publication was updated in May 2024 – First published in February 2023
Defining the type-2 diabetic population: a first step to understanding the impact of pathway choices
Strategic Insight reports are designed to support strategic objectives and planning by Integrated Care System leaders. The aim of this report is to determine current prescribing patterns and prescribing costs of antidiabetic treatments across the ICBs in the North of England with a particular emphasis on SGLT-2 inhibitors and GLP-1 mimetics. This will enable organisations to audit current practices against updated NICE guideline recommendations, and to estimate the financial and resource implications of prescribing SGLT-2s to a wider population.
This publication is part of our Strategic Support and Planning contract. To gain access please email us at nuth.nyrdtc.rxsupp@nhs.net.
Formulary assessment – Glucagon (Ogluo)
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.